| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Alexion Pharmaceuticals Inc (ETR: AXP)
AXP Technical Analysis
4
| As on 30th Oct 2017 AXP Share Price closed @ 110.70 and we RECOMMEND Sell for LONG-TERM with Stoploss of 114.07 & Strong Sell for SHORT-TERM with Stoploss of 118.17 we also expect STOCK to react on Following IMPORTANT LEVELS. |
AXP Share Price
| Open | 111.45 | Change | Price | % |
| High | 112.75 | 1 Day | 0.00 | 0.00 |
| Low | 110.70 | 1 Week | 0.00 | 0.00 |
| Close | 110.70 | 1 Month | -9.50 | -7.90 |
| Volume | 854 | 1 Year | -3.80 | -3.32 |
| 52 Week High 136.65 | 52 Week Low 86.80 | ||||
ETR Germany Most Active Stocks
| DTE | 15.31 | -2.11% |
| DBK | 14.13 | 1.29% |
| EOAN | 10.38 | 2.47% |
| CBK | 11.88 | 0.93% |
| IFX | 24.51 | 4.30% |
| LHA | 28.21 | 2.96% |
| DAI | 73.07 | 2.50% |
| BIR | 0.24 | 0.00% |
| TKA | 23.49 | 2.53% |
| MEO | 29.18 | 0.00% |
ETR Germany Top Gainers Stocks
ETR Germany Top Losers Stocks
| AXP Daily Charts |
AXP Intraday Charts |
Whats New @ Bazaartrend |
AXP Free Analysis |
|
|
AXP Important Levels Intraday
| SUPPORT | 0.00 |
| SUPPORT | 0.00 |
| RESISTANCE | 112.60 |
| RESISTANCE | 111.82 |
| SUPPORT | 109.58 |
| SUPPORT | 108.80 |
| SUPPORT | 0.00 |
| SUPPORT | 0.00 |
AXP Target for Month August
| 4th UP TARGET | 142.78 |
| 3rd UP TARGET | 132.49 |
| 2nd UP TARGET | 126.13 |
| 1st UP TARGET | 119.77 |
| 1st DOWN TARGET | 101.63 |
| 2nd DOWN TARGET | 95.27 |
| 3rd DOWN TARGET | 88.91 |
| 4th DOWN TARGET | 78.62 |
AXP Weekly Target
| 4th UP TARGET | 0.00 |
| 3rd UP TARGET | 0.00 |
| 2nd UP TARGET | 0.00 |
| 1st UP TARGET | 0.00 |
| 1st DOWN TARGET | 0.00 |
| 2nd DOWN TARGET | 0.00 |
| 3rd DOWN TARGET | 0.00 |
| 4th DOWN TARGET | 0.00 |
AXP Target for Year 2021
| 4th UP TARGET | 0 |
| 3rd UP TARGET | 0 |
| 2nd UP TARGET | 0 |
| 1st UP TARGET | 0 |
| 1st DOWN TARGET | 0 |
| 2nd DOWN TARGET | 0 |
| 3rd DOWN TARGET | 0 |
| 4th DOWN TARGET | 0 |
Alexion Pharmaceuticals Inc ( ETR Germany Symbol : AXP )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
AXP Business Profile
Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes life-transforming therapeutic products. It offers Soliris (eculizumab), a therapeutic product to treat paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and atypical hemolytic uremic syndrome (aHUS), a genetic disease. The company also conducts Phase IV clinical trials on Soliris for its usage for the treatment of PNH registry, and aHUS for pediatric and adult; and various Phase II clinical trials for its usage for the treatment of PNH pediatric trial, presensitized renal transplant, delayed kidney transplant graft function, hemolytic uremic syndrome, neuromyelitis optica, myasthenia gravis, and cold agglutinin disease. In addition, it develops Asfotase alfa that is under Phase II clinical trial for the treatment of metabolic disorders, including hypophosphatasia; ALXN 1102/1103, which is in Phase I trial for PNH; ALXN 1007, a novel humanized antibody for treating inflammatory disorders; and cPMP that is in Phase I trial for treating metabolic disorders. The company primarily serves distributors, pharmacies, hospitals, hospital buying groups, and other health care providers, as well as governments and government agencies. Alexion Pharmaceuticals, Inc. has a strategic agreement with Moderna Therapeutics, Inc. for the development of messenger RNA therapeutics to treat rare diseases. The company sells its products primarily in the United States, Europe, and the Asia Pacific. Alexion Pharmaceuticals, Inc. was founded in 1992 and is headquartered in Cheshire, Connecticut.
